Ivosidenib Patent Expiration
Ivosidenib is Used for treating AML, cholangiocarcinoma, and myelodysplastic syndromes with IDH1 mutations. It was first introduced by Servier Pharmaceuticals Llc
Ivosidenib Patents
Given below is the list of patents protecting Ivosidenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tibsovo | US10980788 | Therapy for treating malignancies | Jun 07, 2039 | Servier |
| Tibsovo | US10653710 | Combination therapy for treating malignancies | Oct 18, 2036 | Servier |
| Tibsovo | US10449184 | Pharmaceutical compositions of therapeutically active compounds | Mar 13, 2035 | Servier |
| Tibsovo | US10799490 | Pharmaceutical compositions of therapeutically active compounds | Mar 13, 2035 | Servier |
| Tibsovo | US9968595 | Pharmaceutical compositions of therapeutically active compounds | Mar 13, 2035 | Servier |
| Tibsovo | US9474779 | Therapeutically active compositions and their methods of use | Aug 19, 2033 | Servier |
| Tibsovo | US10717764 | Therapeutically active compounds and their methods of use | Jan 18, 2033 | Servier |
| Tibsovo | US11667673 | Therapeutically active compounds and their methods of use | Jan 18, 2033 | Servier |
| Tibsovo | US9850277 | Therapeutically active compositions and their methods of use | Jan 18, 2033 | Servier |
| Tibsovo | US10610125 | Methods and compositions for cell-proliferation-related disorders | Jun 21, 2030 | Servier |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ivosidenib's patents.
Latest Legal Activities on Ivosidenib's Patents
Given below is the list recent legal activities going on the following patents of Ivosidenib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Apr, 2024 | US9474779 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jan, 2024 | US10717764 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Nov, 2023 | US10653710 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Jun, 2023 | US11667673 |
| Mail Patent eGrant Notification | 06 Jun, 2023 | US11667673 |
| Email Notification Critical | 06 Jun, 2023 | US11667673 |
| Recordation of Patent eGrant | 06 Jun, 2023 | US11667673 |
| Patent eGrant Notification | 06 Jun, 2023 | US11667673 |
| Electronic Review Critical | 06 Jun, 2023 | US11667673 |
| Recordation of Patent Grant Mailed Critical | 06 Jun, 2023 | US11667673 |
Ivosidenib's Family Patents
